Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeremic, B.
Right arrow Articles by Milisavljevic, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeremic, B.
Right arrow Articles by Milisavljevic, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 14, 1065-1070, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

B Jeremic, Y Shibamoto, L Acimovic and S Milisavljevic
Department of Oncology, University Hospital, Kragujevac, Yugoslavia.

PURPOSE: To investigate the efficacy of concurrent hyperfractionated radiation therapy (HFX RT) and low-dose daily chemotherapy (CHT) in stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Between January 1990 and December 1991, 131 patients with histologically or cytologically confirmed stage III NSCLC, Karnofsky performance status (KPS) > or = 50, and no previous therapy were randomly treated as follows: group I, HFX RT with 1.2 Gy twice daily to a total dose of 69.6 Gy (n = 66); and group II, same HFX RT with CHT consisting of 50 mg of carboplatin (CBDCA) and 50 mg of etoposide (VP- 16) given on each RT day (n = 65). RESULTS: Group II patients had a significantly longer survival time than group I patients, with a median survival of 22 versus 14 months and 4-year survival rates of 23% versus 9% (P = .021). The median time to local recurrence and 4-year local recurrence-free survival rate were also significantly higher in group II than in group I (25 v 20 months and 42% v 19% respectively, P = .015). In contrast, the distant metastasis-free survival rate did not significantly differ in the two groups (P = .33). The two groups showed similar incidence of acute and late high-grade toxicity (P = .44 and .75, respectively). No treatment-related toxicity was observed. CONCLUSION: The combination of HFX RT and low-dose daily CBDCA plus VP- 16 was tolerable and improved the survival of patients with stage III NSCLC as a result of improved local control.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
M. J. Edelman, M. Suntharalingam, W. Burrows, K. F. Kwong, N. Mitra, Z. Gamliel, M. Riley, L. B. Cooper, N. L. Kennedy, S. Buskirk, et al.
Phase I/II Trial of Hyperfractionated Radiation and Chemotherapy Followed by Surgery in Stage III Lung Cancer
Ann. Thorac. Surg., September 1, 2008; 86(3): 903 - 910.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Jeremic and C. Koning
Induction Chemotherapy Before Chemoradiation in Locally Advanced Non-Small-Cell Lung Cancer: Failure After Failure, Again and Again
J. Clin. Oncol., April 1, 2008; 26(10): e1 - e2.
[Full Text] [PDF]

Home page
 JCOHome page
B. Jeremic
Low Incidence of Isolated Nodal Failures After Involved-Field Radiation Therapy for Non Small-Cell Lung Cancer: Blinded by the Light?
J. Clin. Oncol., December 10, 2007; 25(35): 5543 - 5545.
[Full Text] [PDF]

Home page
 JCOHome page
A. W. Blackstock and R. Govindan
Definitive Chemoradiation for the Treatment of Locally Advanced Non Small-Cell Lung Cancer
J. Clin. Oncol., September 10, 2007; 25(26): 4146 - 4152.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens
Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 243S - 265S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes, J. E. Herndon II, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. Neill, J. N. Atkins, D. M. Watson, W. Akerley, and M. R. Green
Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B
J. Clin. Oncol., May 1, 2007; 25(13): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski
Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer
Oncologist, July 1, 2006; 11(7): 809 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Auperin, C. Le Pechoux, J. P. Pignon, C. Koning, B. Jeremic, G. Clamon, L. Einhorn, D. Ball, M. G. Trovo, H. J. M. Groen, et al.
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients
Ann. Onc., March 1, 2006; 17(3): 473 - 483.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart
Imaging of the Patient with Non-Small Cell Lung Cancer
Radiology, December 1, 2005; 237(3): 803 - 818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic
Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin/Paclitaxel in Patients With Early-Stage (I/II) Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study
J. Clin. Oncol., October 1, 2005; 23(28): 6873 - 6880.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes
Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 5853 - 5855.
[Full Text] [PDF]

Home page
 JCOHome page
C. P. Belani, H. Choy, P. Bonomi, C. Scott, P. Travis, J. Haluschak, and W. J. Curran Jr
Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol
J. Clin. Oncol., September 1, 2005; 23(25): 5883 - 5891.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E. Vokes, J. Crawford, J. Bogart, M. A. Socinski, G. Clamon, and M. R. Green
Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 5045s - 5050s.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Atagi, M. Kawahara, T. Tamura, K. Noda, K. Watanabe, A. Yokoyama, T. Sugiura, H. Senba, S. Ishikura, H. Ikeda, et al.
Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812)
Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Movsas, C. Scott, C. Langer, M. Werner-Wasik, N. Nicolaou, R. Komaki, M. Machtay, C. Smith, R. Axelrod, L. Sarna, et al.
Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01
J. Clin. Oncol., April 1, 2005; 23(10): 2145 - 2154.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. H. Kim, K. H. Cho, H. R. Pyo, J. S. Lee, J. I. Zo, D. H. Lee, J. M. Lee, H. Y. Kim, B. Hwangbo, S. Y. Park, et al.
Dose-volumetric Parameters for Predicting Severe Radiation Pneumonitis after Three-dimensional Conformal Radiation Therapy for Lung Cancer
Radiology, April 1, 2005; 235(1): 208 - 215.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic
Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study
J. Clin. Oncol., February 20, 2005; 23(6): 1144 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, D. E. Morris, J. S. Halle, D. T. Moore, T. A. Hensing, S. A. Limentani, R. Fraser, M. Tynan, A. Mears, M. P. Rivera, et al.
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non-Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
J. Clin. Oncol., November 1, 2004; 22(21): 4341 - 4350.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Hasegawa, S. Takanashi, K. Okudera, M. Aoki, K. Basaki, H. Kondo, T. Takahata, N. Yasui-Furukori, T. Tateishi, Y. Abe, et al.
Weekly Paclitaxel and Nedaplatin With Concurrent Radiotherapy for Locally Advanced Non-small-cell Lung Cancer: a Phase I/II Study
Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 647 - 653.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Jeremic, B. Milicic, A. Dagovic, Z. Vaskovic, and L. Tadic
Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., September 1, 2004; 22(17): 3540 - 3548.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Jeremic
Reply to the article "Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study", by Groen et al. (Ann Oncol 2004; 15: 427-432)
Ann. Onc., August 1, 2004; 15(8): 1298 - 1299.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. A. Socinski, C. Zhang, J. E. Herndon II, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, J. Crawford, M. C. Perry, S. L. Seagren, et al.
Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
Ann. Onc., July 1, 2004; 15(7): 1033 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al.
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging
Ann. Onc., March 1, 2004; 15(3): 389 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. M. Groen, A. H. W. van der Leest, E. Fokkema, P. R. Timmer, G. D. Nossent, W. J. G. M. Smit, J. Nabers, H. J. Hoekstra, J. Hermans, R. Otter, et al.
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study
Ann. Onc., March 1, 2004; 15(3): 427 - 432.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. Jeremic, F. B. Zimmermann, and M. Molls
Induction chemotherapy followed by concurrent chemoradiotherapy and operation in locally advanced non-small cell lung cancer
Ann. Thorac. Surg., September 1, 2003; 76(3): 979 - 979.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen
A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
F. C. Detterbeck
Changes in the treatment of Pancoast tumors
Ann. Thorac. Surg., June 1, 2003; 75(6): 1990 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Price
Lung cancer * 5: State of the art radiotherapy for lung cancer
Thorax, May 1, 2003; 58(5): 447 - 452.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. S. Albain, J. J. Crowley, A. T. Turrisi III, D. R. Gandara, W. B. Farrar, J. I. Clark, K. R. Beasley, and R. B. Livingston
Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019
J. Clin. Oncol., August 15, 2002; 20(16): 3454 - 3460.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Sekine, Y. Nishiwaki, T. Ogino, A. Yokoyama, M. Saito, K. Mori, I. Tsukiyama, S. Tsuchiya, K. Hayakawa, K. Yoshimura, et al.
Phase II Study of Twice-Daily High-Dose Thoracic Radiotherapy Alternating With Cisplatin and Vindesine for Unresectable Stage III Non-Small-Cell Lung Cancer: Japan Clinical Oncology Group Study 9306
J. Clin. Oncol., February 1, 2002; 20(3): 797 - 803.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Robnett, M. Machtay, J. P. Stevenson, K. M. Algazy, and S. M. Hahn
Factors Affecting the Risk of Brain Metastases After Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Carcinoma
J. Clin. Oncol., March 1, 2001; 19(5): 1344 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. D. Maguire, L. B. Marks, G. S. Sibley, J. E. Herndon II, R. W. Clough, K. L. Light, M. L. Hernando, P. A. Antoine, and M. S. Anscher
73.6 Gy and Beyond: Hyperfractionated, Accelerated Radiotherapy for Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2001; 19(3): 705 - 711.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Jeremic, Y. Shibamoto, B. Milicic, N. Nikolic, A. Dagovic, J. Aleksandrovic, Z. Vaskovic, and L. Tadic
Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial
J. Clin. Oncol., April 7, 2000; 18(7): 1458 - 1464.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. H. Johnson
Locally Advanced, Unresectable Non-Small Cell Lung Cancer : New Treatment Strategies
Chest, April 1, 2000; 117(4_suppl_1): 123S - 126S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. P. Belani
Combined Modality Therapy for Unresectable Stage III Non-Small Cell Lung Cancer : New Chemotherapy Combinations
Chest, April 1, 2000; 117(4_suppl_1): 127S - 132S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. A. Bunn Jr. and K. Kelly
New Combinations in the Treatment of Lung Cancer : A Time for Optimism
Chest, April 1, 2000; 117(4_suppl_1): 138S - 143S.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Atagi, M. Kawahara, M. Ogawara, K. Matsui, N. Masuda, S. Kudoh, S. Negoro, and K. Furuse
Phase II Trial of Daily Low-dose Carboplatin and Thoracic Radiotherapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., February 1, 2000; 30(2): 59 - 64.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. T. Sause
The Role of Radiotherapy in Non-Small Cell Lung Cancer*
Chest, December 1, 1999; 116(suppl_3): 504S - 508S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Koukourakis, S. Koukouraki, A. Giatromanolaki, S. C. Archimandritis, J. Skarlatos, K. Beroukas, J. G. Bizakis, G. Retalis, N. Karkavitsas, and E. S. Helidonis
Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer
J. Clin. Oncol., November 1, 1999; 17(11): 3512 - 3521.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Langer and D. S. Ettinger
The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy
Oncologist, April 1, 1998; 3(2): 67 - 85.
[Abstract] [Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1996 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online